42 results about "Human endometrium" patented technology

An oral contraception regimen which comprises sequentially administering two or more progestational agents exhibiting different effects on the human endometrium in combination with an estrogen. The invention is also directed to an extended use oral contraception regimen comprising the sequential administration of two or more progestational agents in combination with an estrogen.

The invention provides a method for detecting endometrial receptivity through MST1 and phosphorylated MST1. The method comprises the steps that a human endometrial carcinoma cell line Ishikawa and HEK293T cells are kept and cultured in a 10% FBS and mycillin containing double-antibody DMEM/F12 culture solution; an immunoblotting experiment is carried out; co-immunoprecipitation is carried out; immunohistochemistry is carried out; adjustment of MST1 on the transcriptional activity of HOXA10 is analyzed through chromosome co-immunoprecipitation (ChIP)/PCRs; human choriocarcinoma cell (BeWo) sphere adhering experiments are carried out. According to the method, the expression level of MST1 and MST1 phosphorylation modification in endometrial tissue is detected conveniently and fast, and the receptivity state of the endometrium can be directly reflected.

The invention provides a human tumor-related methylation site as well as a screening method and use thereof. The human tumor-related methylation site is selected from at least one methylation site on a human 18th chromosome, a human third chromosome and a human second chromosome; the change of methylation site, caused by BMI, on chromosomes is related to a human endometrial cancer; prognosis on a human tumor can be performed by detecting the methylation site changes on the chromosomes; the human tumor-related methylation site can be used as a potential prognosis marker of the tumor, and especially can be used as a prognosis marker of the human endometrial cancer.

The invention provides a preparation containing endometrium mesenchymal cell exosome, and relates to the technical field of biological stem cells. The preparation comprises, by volume, 5 parts of endometrium mesenchymal cell exosome and 95 parts of matrix solution. The matrix solution comprises 95-99 parts of multiple electrolytes injection liquid and 1-5 parts of medicinal human blood albumin, and endometrium mesenchymal cell exosome is derived from starvation culture of autologous endometrium mesenchymal cells, and the time of the starvation culture is 12-24 hours. The autologous endometriummesenchymal cells are extracted from the mesenchymal stem cells in a human endometrium and cultured by using a normal culture method. The culture time is 48-72 hours. The invention provides a medicine which is safe, effective and convenient to use for treating diseases such as endometrial damage and the like.

Disclosed herein is a method for culturing and proliferating hematopoietic stem cells or progenitor cells. The method comprises co-culturing the hematopoietic stem cells or the progenitor cells with human endometrial stromal cells so as to promote the expansion of hematopoietic stem cell-derived CD34⁺ cells or the growth of the progenitor cells. According to the disclosed method, unlike the prior methods of culturing the hematopoietic stem cells with the addition of cytokines, growth factors or hormones, the hematopoietic stem cells or the progenitor cells are co-cultured with the endometrial stromal cells or epithelial cells so that the number of CD34⁺-enriched hematopoietic stem cells or progenitor cells is increased by factors secreted from the endometrial stromal cells or epithelial cells. Accordingly, it is possible to eliminate the addition of growth factors, such as cytokines, and hormones, which cause problems in transplantation of hematopoietic stem cells or progenitor cells and thus safe hematopoietic stem cells or progenitor cells can be obtained in large amounts.

The invention discloses a protein extraction and treatment process at different time points (including early, middle and late periods of secretion: LH_2, LH_5, LH_7, LH_9, LH_10 and LH_12, and LH_0 on the day of injection of hCG) in a human endometrial tissue secretion period, and a protein spectrum and a phosphorylation modification mass spectrum are carried out to obtain molecular expression modes at different time points in the secretion period. The molecular expression modes can provide a basis for further knowing the dynamic change of the human endometrial tissue secretion period, and is beneficial to judging an endometrial implantation window period and guiding the embryo transplantation time in an assisted reproduction technology.

The invention discloses an endometrial stem cell exocrine concentrated solution gel preparation for treating endometrial injury, a preparation method and a drug administration method of the preparation. A method of starving endometrial stem cells is adopted to obtain a human endometrial stem cell exocrine extract in a short time, and the extract is concentrated through an ultracentrifugation method to obtain a human endometrial stem cell exosome with high concentration, wherein the gel for the human endometrial stem cell exosome contains sodium alginate and a compound electrolyte injection solution as stabilizers, a humectant and a transdermal absorption promoter to form stable and uniform gel-like substances which are beneficial to absorption. The preparation can be used for treating endometrial injury.

The invention provides application of gamabufotalin and a salt compound thereof in preparation of a medicine for treating gynecological tumor. By comparing in vitro anti-cancer experiments of a bufadienolide extract and monomeric compounds, namely the gamabufotalin, cinobufagin, bufalin and bufotalin as well as hydrochlorides or sulfates of the four compounds to four gynecological tumors, namely human ovarian cancer cells A2780, human ovarian cancer cells SK-OV-3, human cervical carcinoma cells and human endometrial cancer cells, an experimental result shows that the gamabufotalin has stronger activity against gynecological tumor cells than the bufadienolide extract and the monomeric compounds, namely the cinobufagin, the bufalin and the bufotalin, and the hydrochloride or the sulfate of the gamabufotalin has stronger activity against gynecological tumor cells than the hydrochlorides or the sulfates of three compounds, namely the cinobufagin, the bufalin and the bufotalin. The gamabufotalin and the salt compound thereof provided by the invention have the advantages of clear components, controllable quality, strong anti-cancer activity, and small adverse reaction, and are expect to be developed into a novel anti-cancer drug.

The present invention relates to a new method for premature ovarian failure treatment, wherein human endometrium stem cells can promote ovarian function recovery. Particularly the present invention discloses applications of human endometrium stem cells in preparation of drugs for premature ovarian failure treatment, specifically in preparation of cell drugs for premature ovarian failure treatment, and/or medical technologies.

The invention provides application of a bufadienolide compound and a bufadienolide salt compound in preparing a medicine for treating gynecological tumor. Anti-cancer experiments of four gynecological tumor, namely human ovarian cancer cells (A2780), human ovarian cancer cells (SK-OV-3), human cervical carcinoma cells (SiHa) and human endometrial cancer cells (shikawa) are carried out in vitro through a bufadienolide extract and monomeric compounds, namely cinobufagin, bufalin, bufotalin and gamabufotalin as well as hydrochlorides or sulfates of the four monomeric compounds, and an experimental result shows that the bufadienolide extract, the monomeric compounds, namely the cinobufagin, the bufalin, the bufotalin and the gamabufotalin, and the hydrochlorides or the sulfates of the four monomeric compounds have strong inhibition effect on four gynecological tumor cells. The anti-cancer activity of the bufadienolide compound and the bufadienolide salt compound is stronger than that of a positive drug paclitaxel, and the bufadienolide compound and a bufadienolide salt compound have small adverse reaction and expect to be developed into a novel anti-cancer drug.

The invention belongs to the technical field of biology, and particularly relates to a stem cell exosome composite preparation for improving premature ovarian failure and an application of the composite preparation. The stem cell exosome composite preparation provided by the invention is formed by compounding human endometrial stem cell exosomes and human umbilical cord mesenchymal stem cells, human endometrial stem cells are selected as a source of the stem cell exosomes, the exosomes are collected after culture, and the exosomes and a certain amount of the highly-active human umbilical cordmesenchymal stem cells are mixed for use to maximize the function of the exosomes and the stem cells, so that the ovarian physiological function can be effectively improved, and ovarian decline can bedelayed. The invention also provides the application of the above stem cell exosome composite preparation in treating the premature ovarian failure and improving hormone secretion.

The invention relates to a method for establishing a human endometritis model in vitro by using berberine to alleviate lipopolysaccharide. The method comprises the steps of (1) isolation and culture of primary human endometrial stromal cells: using primary cell culture in vitro and the secondary screening method to extract 2-3 generations of human endometrial stromal cells; (2) utilizing the CCK8method to screen the appropriate concentration and time of LPS on the cells; (3) adopting the CCK8 method to screen the appropriate concentration and time of BBR on the cells; (4) detecting the content of IL-1 beta and TNF-alpha by ELISA; (5) data analysis. The CCK8 method is adopted to detect the toxic effects of different concentration gradients of LPS and BBR on hESCs at the different time, andthe ELISA method is utilized to identify an LPS-induced inflammation model to determine that berberine has a certain curative effect on human endometritis and is a potential drug for treating the endometritis.

The invention relates to application of chemical drugs in the field of medicine, in particular to application of glycocholic acid in preparation of antitumor drugs. The novel applicable field of glycocholic acid is provided herein; glycocholic acid is applicable to the preparation of antitumor drugs, mainly for breast cancer, ovarian cancer, endometrial carcinoma, lung cancer or their combinations; as an effective active ingredient to antitumor drugs, glycocholic acid has effective treatment quantity of 4T1 (mouse breast cancer cells) under 0.4-1.6 nmol/L, and MCF-7 (human breast cancer cells), NIH OVCAR-3 (human ovarian carcinoma cells), RL95-2 (human endometrial cancer cells), and HCC827 (human non-small cell lung cancer cells) under 16-128 mu mol/L. The application is helpful for the development of novel antitumor drugs.

The invention discloses a method for establishing an embryo in vitro implantation model and the user thereof, and the method comprises the courses of: endometrium selection, separate culture and deciduate induction of substrate cells of human endometrium and, embryo culture, co-culture of human embryo and substrate cells of deciduate endometrium, etc, and because it establishes a model of in vitro co-culturing substrate cells of deciduate human endometrium and human embryo and has observed the whole implantation course of human embryo, including adhesion, epitaxial growth and invasion. And the model is nearer to human embryo in vitro implantation environment, and can be used to make a series of researches on related influence factors of embryo implantation, implements in vitro observation of human embryo implantation and provides conditions for researching human embryo implantation mechanism. And the invention can improve sterility curing level and auxiliary procreation technical level, and has great social and economical benefits.

The invention belongs to the technical field of medicines, and relates to uses of loganetin in preparation of antitumor medicines. Tumors here include mammal gastric cancer, liver cancer, esophagus cancer, colorectal cancer, pancreatic cancer, lung cancer, head and neck cancer, leukemia, malignant lymphoma, prostatic cancer, breast cancer, glioma, carcinoma of bile duct, melanoma, kidney cancer, ovarian cancer, endometrial cancer and cervical cancer, and more specifically, human gastric cancer, human liver cancer, human esophagus cancer, human colorectal cancer, human pancreatic cancer, human lung cancer, human head and neck cancer, human leukemia, human malignant lymphoma, human prostatic cancer, human breast cancer, human glioma, human carcinoma of bile duct, human melanoma, human kidney cancer, human ovarian cancer, human endometrial cancer and human cervical cancer. In-vitro and in-vivo tests prove that the loganetin can inhibit the tumors well, shows good tumor growth inhibiting activity, and has great potential in development into antitumor medicines.

The present invention discloses a human endometriosis cell, EM 257, which has been stored in the food industry research and development institute. Results obtained from a flow cytometry reveal that the human endometriosis cell of the present invention is positive for the mesnchymal stem cell surface antigens, such as CD44, CD73, CD105 and CD146. In different differentiation conditions, the human endometriosis cell of the present invention can be differentiated into osteogenic or adipogenic lineage cells.

The invention provides a method for evaluating endometrial receptivity of a patient and a kit for performing the method. According to the invention, the human endometrial receptivity functional statusis determined by using RNA or DNA sequencing (e.g., by NGS (next generation sequencing)) of a living tissue examination material from the endometrium, and using the expression of 248 genes related tothe endometrial receptivity status or a specific sub-combination thereof (as shown in Figure 1). Based on analysis, specific computational predictors classify samples according to their expression profiles in corresponding endometrial stages (proliferation stage, pre-receptive stage, early receptive stage, receptive stage, late receptive stage or post-receptive stage). It should be noted that thereceptivity statuses can be assigned through subsequent analysis of expression profiles of a specific gene set by the computational predictors.

The present invention relates to a molecular marker CD71 and applications in diagnosis, staging and prognosis of endometrial carcinoma, and belongs to the field of molecular biology, wherein the molecular marker is human transferrin receptor 1 (CD71). According to the present invention, by using the anti-human transferrin receptor 1 (CD71) antibody, the results show that human transferrin receptor 1 (CD71) is not expressed or extremely little expressed in normal endometrial tissue and precancerous lesion tissue, is specifically and highly expressed in human endometrial carcinoma tissue, and is related to the staging and the prognosis of endometrial carcinoma, such that CD71 can be used in the diagnosis, the clinical staging and the prognosis of endometrial carcinoma tissue.

Provided is a method of producing a cell having properties of endometriosis (hereinafter referred to as “endometriotic-like cell”) from a human mesenchymal stem cell. Also provided are a method of producing an animal model exhibiting human endometriosis, the method including transplanting the cell to an animal, and an animal model of endometriosis. The method of producing an endometriotic-like cell comprises a step of culturing a human mesenchymal stem cell induced to differentiate by allowing a differentiation inducing agent to act on the cell, through use of a low-carbon-source culture medium free of a differentiation inducing agent, in a culture vessel coated with extracellular matrix.

The invention discloses a preparation method and application of a human endometrial stem cell compound repair factor. The preparation method specifically includes the following steps that a human endometrial stem cell is separated from human endometrial tissue; in-vitro digestion separation and expanded culture is performed on the human endometrial stem cell to obtain a high-quality human endometrial stem cell; industrialized amplification culture is performed on the high-quality human endometrial stem cell, and stem cell culture supernatants of the P3-P6 generations are collected; the stem cell culture supernatants are subjected to concentration, protein content determination and quality inspection to obtain a human endometrial stem cell concentration factor; the human endometrial stem cell concentration factor is mixed with a freeze-drying protective agent, and then freeze-drying is conducted to obtain human endometrial stem cell freeze-dried powder; and the human endometrial stem cell freeze-dried powder is mixed with a solvent to obtain the human endometrial stem cell compound repair factor. The repair factor has a remarkable treatment effect, a patient is free of pain, an operation and a surgery are not required, no side effect is caused, and the factor is safe and efficient.

The invention discloses a strain of endometrial adenocarcinoma cell lines, wherein a name of the endometrial adenocarcinoma cell lines is LHY-821, and a preservation register number of the endometrial adenocarcinoma cell lines is CGMCC No.4066. The LHY-821 cell lines has advantages of uniform cell morphology, good cell growth, strong adhesive ability, doubling time of 44-48 hours and stable biological characteristics and genetic property. The LHY-821 cell lines can be applicable for research on biology of tumor cells, molecular biology, gene and epigenetics in vitro and in vivo, and on therapeutic effects of new antitumor drugs in a preclinical phase, and has a wide application prospect.